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Objectives Clozapine is an atypical antipsychotic primarily
prescribed for treatment-resistant schizophrenia. We tested
the specific effect of clozapine versus other drug treatments
on whole-blood gene expression in a sample of patients
with psychosis from the UK.
Methods A total of 186 baseline whole-blood samples
from individuals receiving treatment for established
psychosis were analysed for gene expression on Illumina
HumanHT-12.v4 BeadChips. After standard quality-control
procedures, 152 samples remained, including 55 from
individuals receiving clozapine. In a within-case study
design, weighted gene correlation network analysis was
used to identify modules of coexpressed genes. The
influence of mood stabilizers, lithium carbonate/lithium
citrate and sodium valproate was studied to identify their
possible roles as confounders.
Results Individuals receiving clozapine as their only
antipsychotic (clozapine monotherapy) had a nominal
association with one gene-expression module, whereas no
significant change in gene expression was found for
other drugs.
Conclusion Overall, this study does not provide evidence
that clozapine treatment induces medium to large different
gene-expression patterns in human whole blood versus
other antipsychotic treatments. This does not rule out the
possibility of smaller effects as observed for other common
antipsychotic treatments. Psychiatr Genet 00:000–000
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Introduction
Psychosis is a common symptom of several psychiatric
disorders, including bipolar disorder and schizophrenia.
Schizophrenia has a lifetime prevalence of 1%. Up to 30%
of schizophrenic patients develop treatment-resistant
schizophrenia that is diagnosed after unsuccessful treat-
ment with two or more typical antipsychotics (Meltzer,
1997). Clozapine is considered a ‘drug of last resort’ in
these patients as, despite its well-documented side
effects, clozapine can lead to significant clinical
improvements (Kane, 1992; Agid et al., 2007; Cohen et al.,
2012). However, around 50% of treatment-resistant
patients respond poorly to clozapine (Lieberman et al.,
1994).
Early identification of patients who may benefit from
clozapine treatment is not currently possible. On average,
there is a 4-year delay in starting clozapine because
of prescribing guidelines, side effects, uncertainty of
response and the need for regular blood monitoring
during treatment (Howes et al., 2012). Clozapine
response can take up to a year to stabilize, meaning that
long-term clozapine treatment is required before schizo-
phrenia is defined as clozapine nonresponsive (Meltzer,
1989). Clozapine response biomarkers could help iden-
tify suitable candidates for clozapine treatment or be
useful for early termination of unsuccessful trials. This
would minimize the detrimental effects associated with
persistent psychotic symptoms.
Previous evidence for clozapine-induced changes in gene
expression mainly derives from animal studies. In mouse
brain, Duncan et al. (2008) found that haloperidol, clo-
zapine and olanzapine generally decrease gene expres-
sion, including for potassium channel subunits. In mice,
clozapine has been reported to alter the expression of
glutamate receptor g2 subunits and ubiquitin-conjugating
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enzyme E2R, whereas both clozapine and haloperidol
modify the expression of genes associated with apoptosis,
proteolysis and lipid metabolism (Thomas et al., 2003).
In rats, long-term clozapine exposure identified 278
downregulated genes and 73 upregulated genes in the
frontal cortex relative to controls (Fatemi et al., 2012).
The genes identified were involved in pathways such as
protein metabolism, nucleotide metabolism and signal
transduction (Fatemi et al., 2012). Clozapine and other
atypical antipsychotics have also been shown to alter the
metabolism of cholesterol and fatty acids in vivo. Cells
treated with clozapine have significantly higher levels
of SREBP (sterol-regulatory element-binding protein),
HMGR (HMG-CoA reductase) and LDLR (LDL
receptor) mRNA than control cells (Canfrán-Duque et al.,
2013). Studies have also shown that other drugs such as
lithium and valproate may also influence gene expression
(Phiel et al., 2001; Brandish et al., 2005; Sharp et al., 2013).
As clozapine-treated patients may receive other non-
antipsychotic medications, it is important to avoid the
confounding effects induced by other medications.
Global expression changes in blood have been observed
to correlate with those in the brain. The correlation
between transcripts present in both central nervous sys-
tem and whole blood was ∼ 0.5 (Sullivan et al., 2006). Of
the candidate schizophrenia genes investigated, half were
expressed in whole blood and the prefrontal cortex
(Sullivan et al., 2006). Using a methodology similar to that
of the current study, De Jong et al. (2012) found two gene
coexpression modules enriched for brain-expressed
genes in whole blood in schizophrenic patients. A
recent study examining DNA methylation in response to
antipsychotics and mood stabilizers (including lithium
and valproic acid) found that these medications influence
cell-type composition and that psychotropic medications
investigated influenced DNA methylation at both the
gene and the network level (Houtepen et al., 2016).
Given the previous evidence that clozapine may influ-
ence gene expression, we hypothesize that antipsychotic
medications could have a detectable effect on blood
expression in whole blood. In this study, we aimed to
clarify the specific effects of clozapine treatment on gene
expression in whole blood of psychosis patients using
both a single gene and a network-driven analysis
approach (Zhang and Horvath, 2005; Langfelder and
Horvath, 2008).
Methods
The data presented here were collected previously as
part of the IMPACT randomized controlled trial. This
aimed to improve physical health by addressing issues
such as substance use, poor diet and lack of exercise
through cognitive behaviour therapy (Gaughran et al.,
2013).
Ethical approval
Ethical approval was obtained from The Joint South
London and Maudsley and The Institute of Psychiatry
NHS Research Ethics Committee (REC ref no. 09/
H080/41).
Cohort description
The patients recruited to IMPACT were between 18 and
65 years of age, with the following ICD 10 psychiatric
diagnoses: F20–F29 (schizophrenia, psychotic disorders
and schizoaffective disorder), ICD 10 F31.2 (bipolar) and
ICD 10 F32.3, F33.3 (depressive episode with psychotic
symptoms). Exclusion criteria were as follows: learning
disability, a physical health problem that would influence
metabolic measures or substance use habit, pregnancy or
less than 6 months postpartum or under intensive care
[for further details, see Gaughran et al. (2013)]. A total of
186 patients provided consent for prerandomisation
bloods for gene expression. In all, 152 remained follow-
ing quality control and removal of outliers. Outliers were
defined as those with insufficient clinical data, inade-
quate quality information or technical outliers. The main
attributes of this sample are shown in Table 1. The
clinical diagnoses, stratified by clozapine medication
status, are shown in Table 2. Out of 152 individuals, 104
had a diagnosis of schizophrenia, 19 had a diagnosis of
bipolar disorder, 18 had a schizoaffective disorder and six
had a depressive disorder with psychosis. The less com-
mon diagnoses included one with schizotypal disorder,
one with delusional disorder and three with ‘Other non-
organic psychosis’. Only 148 individuals had scores on
the positive and negative symptom score (Leucht et al.,
2005). The mean positive and negative symptom score
was 50 ± 12. The distribution of drugs shown in Table 3 is
not mutually exclusive as some individuals were receiv-
ing several antipsychotics or other medications.
Gene-expression data preprocessing
RNA samples were extracted from postfasting samples
using Tempus Blood RNA tubes according to the
Table 1 Attributes of the 152 individuals drawn from the IMPACT
sample divided into nonclozapine (n=97) and clozapine treatment
groups (n= 55)
Attribute Total sample
Nonclozapine
group Clozapine group
Sample size 152 97 55
Age (mean ±SD) (years) 45 ±9.34 45 ±9.55 43 ±8.95
Male 90 50 40
Female 62 47 15
Caucasian 77 45 32
Black 57 39 18
Asian 7 5 2
Mixed 7 4 3
Other 4 4 0
RIN (mean ±SD) 8.64 ± 0.77 8.56 ±0.85 8.72 ±0.79
RNA concentration
(mean ±SD)
83.52 ±36.21 83.29 ±35.85 83.94 ±37.08
RIN, RNA integrity number.
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manufacturer’s protocol (Applied Biosystems, Foster
City, California, USA). Whole-genome gene-expression
data were generated using Illumina HumanHT-12.v4
BeadChips according to the manufacturer’s protocol at
the in-house BRC BioResource Illumina Core laboratory.
Quality control and preprocessing used a standard pipe-
line (BRC Bioinformatics pipeline, URL 1: https://github.
com/snewhouse/BRC_MH_Bioinformatics) that excluded
sample and probe outliers and applied robust spline
normalization and log2 transformation (Du et al., 2008). In
all, 154 individuals passed quality control and after
removing additional sample outliers using the weighted
gene coexpression network analysis (WGCNA) package
(Zhang and Horvath, 2005; Langfelder and Horvath,
2008), 152 patients and 6357 probes remained for sub-
sequent analysis. We applied principal component ana-
lysis (Stacklies et al., 2007) to identify the correlation with
possible covariates (see Supplementary digital content,
Table 1S, Supplemental digital content 1, http://links.lww.
com/PG/A158). The raw expression data were corrected
using age, sex, RNA integrity number, RNA concentra-
tion and ethnicity as covariates. This was done using the
lmFit function of the Limma R package in a linear model
(Smyth, 2004, 2005). This generated residuals, which
were used in subsequent modelling of the association
of drug treatment with gene-expression data. In total,
six models were tested. These included a test for the
association of clozapine, lithium, valproate, other anti-
psychotics, clozapine monotherapy and clozapine poly-
therapy with changes in gene expression.
Identification of significant genes
Individual gene-level analysis tested for an association of
drug treatment (clozapine, valproate, lithium and other
antipsychotics) with expression changes in individual
genes. The association was tested by a linear model in R,
with the untested drug treatments as covariates. The
significance threshold for individual probes was below a
Holm–Sidak-corrected P-value of 0.05. The Holm–Sidak
method is a more conservative measure of multiple
testing easily applied to module eigengene analyses.
Power calculation
Given a sample size of 55 for the clozapine-treated
group and 6357 probes, we had 80% power to detect
1.3-fold expression changes and 99% power to detect
1.5-fold changes (false discovery rate = 0.05, SD= 0.7)
(Bioinformatics M.D. Anderson microarray power calcu-
lator, URL 2: http://bioinformatics.mdanderson.org/Micro
arraySampleSize/).
Weighted gene coexpression network analysis
WGCNA (Zhang and Horvath, 2005; Langfelder and
Horvath, 2008) is a systems biology method used to
analyse microarray expression data in a network context.
First, the pairwise Pearson correlations calculated
between all genes produce a correlation matrix. When
raised to a power, this correlation matrix yields an adja-
cency matrix of the pairwise connection of each gene.
As the power increases, the fit of this network to the
scale-free topology model is improved (Supplementary
digital content, Figure 1S, Supplemental digital content 2,
Table 2 Clinical diagnoses of 152 individuals stratified by clozapine medication status
Diagnosis Total sample Nonclozapine group Clozapine group
Schizophrenia 59 35 24
Paranoid schizophrenia 43 21 22
Residual schizophrenia 1 0 1
Simple schizophrenia 1 1 0
Schizoaffective disorders 9 7 2
Schizoaffective disorder, manic type 4 2 2
Schizoaffective disorder, depressive type 2 1 1
Schizoaffective disorder, mixed type 2 2 0
Schizoaffective disorder, unspecified 1 0 1
Schizotypal disorder 1 1 0
Delusional disorder 1 1 0
Other nonorganic psychotic disorders 1 1 0
Unspecified nonorganic psychosis 2 2 0
Severe depressive episode with psychotic symptoms 4 3 1
Recurrent depressive disorder, current episode severe with psychotic symptoms 2 2 0
Bipolar affective disorder, current episode manic with psychotic symptoms 19 18 1
Table 3 Distribution of antipsychotic treatments and other
medications among the clozapine (n= 55) and nonclozapine-
treated cohort (n= 97)
Medication
Total
sample Nonclozapine cohort
Clozapine
cohort
Quietapine 10 9 1
Depixol 12 12 0
Amisulpiride sulpiride 18 8 10
Aripiprazole 20 12 8
Risperidone 16 16 0
Olanzapine 14 14 0
Clozapine 55 0 55
Clozapine monotherapy 39 39
Clozapine polytherapy 16 16
Other antipsychotics 17 11 6
Antidepressants 82 60 22
Benzodiazepines 19 5 14
Valproate 17 8 9
Lithium 18 9 9
These numbers are not mutually exclusive as many individuals received several
antipsychotics or other medications.
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http://links.lww.com/PG/A159). Here, we chose a power of
11 as this exceeded the 0.9 R2 value, thus ensuring that
highly connected genes were given priority. Our
unsigned network accounted for the absolute correlations
of genes in either direction.
Genes are subsequently clustered using the topological
overlap matrix (TOM) in a gene dissimilarity measure
(1−TOM). This considers each gene pair relative to all
other genes taking into account ‘shared neighbours’.
Branches of the dendrogram are cut using the
DynamicTreeCut algorithm (D’haeseleer, 2005), assign-
ing each gene to a module represented by a colour. A
module eigengene for each module is defined by taking
the first principal component of the expression values per
module. Therefore, the module eigengene represents a
summary of the expression profile of all genes in a
module for each sample. The module eigengenes are
tested for association with drug treatment using a linear
model in R (Smyth, 2005). We tested the association of
each module with clozapine, valproate, lithium and ‘other
antipsychotic’ treatment. As for the individual gene-level
analysis, the covariates used were the drug treatments
that were not being tested. Clozapine monotherapy and
polytherapy was also tested in this way. We define clo-
zapine monotherapy as individuals receiving clozapine as
their only antipsychotic (n= 39). However, all individuals
on clozapine were receiving additional medications,
including antidepressants, benzodiazepines or mood sta-
bilizers. Clozapine polytherapy was defined as being on
clozapine and other antipsychotics (n= 16).
Significance thresholds
WGCNA alleviates the multiple-testing problem by
relating relatively few modules to traits rather than
thousands of probes. To determine significance thresh-
olds, the matSPD spectral decomposition approach by
Dale Nyholt was used (URL 3: http://neurogenetics.qimr
berghofer.edu.au/matSpD/). The P-values generated from
the association of lithium, valproate, clozapine and other
antipsychotics were used to create a correlation matrix,
from which the number of independent variables was
measured (Nyholt, 2004; Li and Ji, 2005) This yielded a
total of seven independent tests from 11 correlated tests
(the total number of modules). For the full cohort of 152
individuals, four further tests were carried out.
Therefore, the independence threshold was defined as
0.05/(7× 4)= 0.0018.
Significant genes and pathways were characterized using
Entrez IDs in WebGestalt (Zhang et al., 2005; Wang et al.,
2013). Pathway analysis utilized Gene Ontology (version
1.2) and KEGG pathways, referenced against all probes
passing quality control, a hypergeometric statistical
model and Holm–Sidak correction for multiple testing
(P< 0.05). Each gene category was required to contain at
least two genes.
Results
Single-gene analysis
After correcting for age, sex, ethnicity, RNA con-
centration and RNA integrity number, the residuals of
each gene were tested for association with clozapine,
valproate, lithium and other antipsychotic treatment.
The covariates were the above drug treatments,
excluding the drug that was being tested. At the single
gene level, no individual gene reached significance for
association with clozapine, lithium, valproate or other
antipsychotics according to the Holm–Sidak threshold
of 8.068× 10− 6.
Network construction
Figure 1 shows the dendrogram representing the
unsigned network from 152 individuals and 6357 probes.
The network contains 11 modules, with sizes ranging
from turquoise (1118 probes) to purple (39 probes). The
grey module (2781 probes) represents genes not
belonging to any other module (background noise).
No association of module eigengenes with clozapine
treatment
A linear model was used to test associations of module
eigengenes with clozapine, valproate, lithium and other
antipsychotics (all antipsychotics except clozapine) treat-
ment with covariates as described in the Methods section,
excluding the tested treatment. No modules were sig-
nificantly associated with clozapine treatment, lithium,
valproate or other antipsychotics (Supplementary digital
content Tables 2S–5S, Supplemental digital content 3,
http://links.lww.com/PG/A160; Supplemental digital con-
tent 4, http://links.lww.com/PG/A161; Supplemental digital
content 5, http://links.lww.com/PG/A162; Supplemental
digital content 6, http://links.lww.com/PG/A163, which pre-
sent the statistics of each module association with drug
treatment).
Clozapine antipsychotic monotherapy
A possible confound was polypharmacy within the clo-
zapine group. We defined a clozapine monotherapy
group of individuals receiving clozapine as their only
antipsychotic. All individuals on clozapine were receiving
additional medications, including antidepressants, ben-
zodiazepines or mood stabilizers.
We tested for association between module eigengenes
and clozapine antipsychotic monotherapy (n= 39) versus
polytherapy (n= 16) with lithium and valproate as co-
variates (Table 4). The strongest association was between
clozapine monotherapy and the purple module
(P= 0.002), just above our significance threshold
(P< 0.0018). This was a downregulation of expression.
This purple module contained 36 genes (represented by
39 probes), the functions of which included cell junctions
and adhesion, platelet degranulation (P= 0.0297), blood
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coagulation (P= 0.0009), wound healing (P= 0.0033) and
muscle contraction (P= 0.0093).
Enrichment analyses using WGCNA gene lists
(UserListEnrichment) also indicated that the purple
module was significantly enriched for platelet-expressed
genes. The purple module was enriched for the top
50 marker genes for platelets (P= 0.86× 10− 6) and for
platelet-specific genes from a custom microarray
(P= 4.85× 10− 16) according to Gnatenko et al. (2009,
2010). Using KEGG (URL 4: http://www.genome.jp/kegg/
pathway.html) pathway terms, this module is enriched for
ECM receptor interaction (P= 0.0143). To our knowl-
edge, none of these genes have been implicated pre-
viously in clozapine response. Of the genes implicated
in cell junctions, one of potential interest is YWHAH
(tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, eta polypeptide). This is an adapter
protein of the 14-3-3 family, which has been implicated
previously in schizophrenia (Toyooka et al., 1999). None of
the other genes within this module appear to have been
reported in schizophrenia studies.
Discussion
This study used a naturalistic, cross-sectional, within-case
design with the aim of identifying specific effects of
clozapine on gene expression relative to other anti-
psychotics. We applied WCGNA to whole-blood gene-
expression data of 152 individuals with psychosis to
examine gene–trait associations at a network level. None
of the 11 gene coexpression modules showed a sig-
nificant association with clozapine treatment. Clozapine
monotherapy (clozapine as the only antipsychotic) may
induce small differences in gene expression.
The distribution of the diagnoses between the clozapine
and the nonclozapine groups was similar, with the
exception of bipolar disorder. We investigated the effect
of bipolar diagnosis on the association of the module
eigengenes to clozapine monotherapy treatment in a
linear model (Supplementary digital content, Table 6S,
Supplemental digital content 7, http://links.lww.com/PG/
A164). This did not have a major effect on the final
associations, and was therefore not included as a covariate
in primary analyses, given that this was a study on the
effects of clozapine medication and the distribution of
mood stabilizers was equal between the two groups.
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The network was constructed using gene-expression data of 6357 probes of 152 individuals with psychosis, of whom 55 were medicated with
clozapine. The dendrogram was produced using hierarchical clustering and modules were grouped and assigned colours by cutting the tree using the
DynamicTreeCut procedure. The asterisk indicates the purple module, associated with clozapine monotherapy treatment.
Table 4 P-value association of each module with clozapine
monotherapy (n=39) and polytherapy (n= 16) in 152 individuals
Module
P-value for association with
clozapine polytherapy
P-value for association with
clozapine monotherapy
Pink 0.317 (−0.999) 0.204 (−1.270)
Blue 0.005 (−2.832) 0.236 (1.187)
Red 0.222 (−1.221) 0.990 (0.013)
Brown 0.185 (1.328) 0.374 (−0.889)
Purple 0.110 (1.597) 0.002* (−3.065)
Green 0.0293 (2.181) 0.547 (−0.603)
Yellow 0.004 (2.914) 0.530 (0.628)
Magenta 0.660 (0.440) 0.122 (1.548)
Black 0.164 (1.391) 0.786 (0.272)
Turquoise 0.212 (1.249) 0.906 (−0.118)
Grey 0.0288 (−2.189) 0.365 (0.906)
t-values are shown in brackets. Each module was generated from corrected
residuals. Module eigengenes summarizing the modules were tested for asso-
ciation with clozapine therapy, corrected for lithium and valproate in a linear model.
*P-values near the significance threshold (P=0.0018).
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The ability to find clozapine-specific effects may be
confounded by other medications causing global effects
in gene expression (De Jong et al., 2012), although this
was not evident here. No individual antipsychotic had
significant effects on gene expression (data not shown)
and other antipsychotics were corrected for as a single
group. Correction for mood stabilizers was justified to
avoid lithium or valproate treatment confounding gene
expression in clozapine-treated individuals. It was also
not possible in our study to distinguish between
expression changes because of refractory schizophrenia
and those because of the effects of medication. Given
that clozapine is known to induce agranulocytosis in 0.8%
of patients on clozapine, we considered whether this
could be an explanation for the enrichment of blood cell-
type markers here (Alvir et al., 1993). However, in this
sample, the likely prevalence would be less than one
individual, which is not likely to have a significant effect
on the results shown here.
Our study had some limitations because of the hetero-
geneity of the cohort used (Table 1). We corrected for
this using age, sex and principal components, and are
confident that this has controlled for any major influences
on gene expression. Another potential limitation was the
heterogeneous medication received by individuals as
only 39 received antipsychotic monotherapy of clozapine.
However, this sample represents the reality of a sample
derived from a retrospective clinical trial. This means that
any findings are more likely to be applicable to clinical
practice but, equally, our study has more potential con-
founding factors.
Searching for expression changes directly related to
pathology in whole blood is more difficult than in brain
tissue, although it has been shown that whole-blood
expression profiles correlate with brain expression
abnormalities in schizophrenic patients (Davies et al.,
2012; Liu et al., 2014). Also, given that clozapine exerts
effects on blood cells, it is reasonable to expect these
changes to be reflected in a gene-expression profile.
Finally, a blood biomarker may be more useful in pre-
dicting treatment response than a brain biomarker
because of ease of access to tissue, and could improve
diagnostics and treatment of patients.
Concluding remarks and further work
The current study found no gene-expression changes
related to clozapine, lithium or valproate use on a gene-
by-gene or network level. However, a potentially inter-
esting nominal association was found for clozapine
monotherapy. The current study is limited by the rela-
tively small sample size used and our within-case design,
which resulted in insufficient power to detect very small
changes in gene expression. Further work could use a
larger sample size and take into account the duration of
clozapine treatment and other factors, such as the likely
epigenetic effects of longer term clozapine treatment.
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